Bayer faces potential delays for its proposed $7.25 billion settlement involving thousands of Roundup cancer claims. An opposing attorney escalated legal disputes by moving the case from a Missouri state court to federal court. Bayer describes this move as baseless but acknowledges it could disrupt approval deadlines.
The company currently awaits a U.S. Supreme Court decision regarding state-level lawsuits. This ruling remains critical for managing long-term liabilities from the 2018 Monsanto acquisition.
Bayer maintains that glyphosate, the main ingredient in Roundup, is not carcinogenic. The company cites Environmental Protection Agency findings to support its position. Plaintiffs rely on conflicting research from a World Health Organization agency.